PV Reporter

11/07/2025

🤘Friday funny!

---> Not medical advice...please consult your physician.

11/06/2025

🧬 Eilean Therapeutics LLC announces its novel drug candidate, ZE74‑0282, a first-in-class JAK2­JH2/V617F inhibitor that spares wild-type JAK2, potentially reducing side effects, improving outcomes and possibly disease-modifying therapy for patients with JAK2 V617F-driven myeloproliferative disorders.

The company will present preclinical data at American Society of Hematology (ASH) 2025 and plans to begin human studies in December 2025.

/PRNewswire/ -- Eilean Therapeutics LLC, a biotechnology company developing next-generation precision medicines for cancer and immune-inflammatory diseases,...

11/06/2025

🔬 Research in myeloproliferative neoplasms (MPNs) is advancing faster than ever.

The launch of Alethio Therapeutics marks a major step forward in developing next-generation treatments that target the root causes of these diseases.

Their programs focus on attacking malignant stem cells and key genetic drivers like mutant CALR. This is a powerful sign that the field is shifting from symptom control toward real disease-modifying therapies.

We’ll be following this progress and sharing updates with the MPN community.

🌐 For more information, visit:
🔗 PV Reporter – pvreporter.com
🔗 MPN Cancer Connection – mpncancerconnection.org

https://finance.yahoo.com/news/alethio-therapeutics-launches-ceo-chair-090000246.html

Rohit Batta CEO, Alethio Therapeutics Mike Grey Chair, Alethio Therapeutics Leveraging deep scientific and clinical expertise in MPNs to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cellsAdvancing AT-01, a first-in-class ADC programme, with strong...

11/03/2025

🚀 ASH 2025: A New Era of MPN Precision Medicine is Here!

I am very proud and happy to be attending the American Society of Hematology (ASH) Annual Meeting in December (in Orlando) for the 11th consecutive year!

This year, one area of focus that is truly poised to change treatment for the MPN community: Highly Targeted Therapies for CALR-Mutated Disease. It's early stage, but these approaches look promising.

I want to spotlight two impactful abstracts, both focused on the 20-30% of MPN patients who have the CALR driver mutation.

Highlight 1: The Smart Bomb Approach
Abstract: Discovery of first-in-class CALR-targeted precision ADCs delivering a CDK9 degrader payload for the treatment of CALR-mutated MPNs. (Prelude Therapeutics)

The Big Idea (The "Smart Bomb"): This is a new type of therapy called a Precision Antibody-Drug Conjugate (ADC). It acts like a guided missile that attaches directly to the abnormal mutant CALR protein found only on the surface of the malignant MPN cells.

The Impact: It then delivers a potent drug payload right inside the cell to destroy it, aiming to eliminate the disease-causing stem cells while leaving healthy cells alone. This is the definition of disease-modifying potential.

Highlight 2: The First-in-Class Antibody
Abstract: Safety And Efficacy Of INCA033989, A Novel First In Class Mutant Calreticulin-Specific Monoclonal Antibody, in MF/ET (Incyte)

The Big Idea (The "Blocker"): This is a monoclonal antibody designed to be the very first to directly target the mutant CALR protein. Instead of delivering a killer payload, it aims to block the abnormal signaling caused by the mutant CALR protein in the disease.

The Impact: The abstract will share important Phase 1 clinical data on its safety and effectiveness in patients with Myelofibrosis (MF) and Essential Thrombocythemia (ET) who haven't responded well to standard therapies. This is a critical next step in moving this new drug class toward approval.

🎯 The Takeaway: Expertise Meets Precision
The fact that two different companies are presenting powerful, novel, targeted agents for CALR-mutated MPNs is a huge win for patients. It confirms that targeting the mutant CALR protein is a validated strategy.

Furthermore, it’s worth noting the deep bench of experience behind these innovations: The CEO of Prelude Therapeutics, Dr. Kris Vaddi, was a Founding Scientist at Incyte Corporation and championed the Jakafi (ruxolitinib) research programs! We are seeing the veterans of MPN drug development apply their expertise to the next generation of precision treatments.

This is just one example that caught my eye, I will share more in the upcoming days. And before you ask, YES there are advances on JAK2 targeting as well.

Search here if you want to check out the abstracts from ASH 2025: https://submit.hematology.org/program

Be sure to visit https://www.pvreporter.com/ your MPN Resource Hub.

PV Reporter was created to provide “easy access” to pertinent information on Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF)

10/27/2025

Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2V61F VAF of 48.5% from baseline.

Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the...

10/23/2025

Rapid Completion of Phase 2 Enrollment Reflects Ongoing Momentum for Divesiran as First-in-Class siRNA for PV

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced it has comp...

10/17/2025

Heterozygous human JAK2V617F activates AhR to drive essential thrombocythemia and promote thrombosis (abstract)

Plain English:

Why the same JAK2 mutation can cause ET or PV

New research helps explain why JAK2V617F can look like two different diseases. It depends on whether one gene copy is mutated or both. In cells with one copy, the signal leans toward making platelets. With two copies, the signal leans toward making red cells. That split maps to ET vs PV.

Quick takeaways:

One mutated copy → pairs with normal JAK2 → turns on STAT1 and AhR → more megakaryocytes → higher platelets → ET.

Two mutated copies → pairs with itself → turns on STAT5 → more red blood cells → PV.

AhR may also make platelets more active through the COX-2 → TXA2 pathway, which can matter for clot risk.

In a humanized ET mouse model, blocking AhR reduced high platelets. The research is still in its early stages, but it shows promise.

Stay informed with practical MPN education at PV Reporter: https://www.pvreporter.com/

https://rupress.org/jem/article-abstract/222/12/e20250153/278371/Heterozygous-human-JAK2V617F-activates-AhR-to?redirectedFrom=fulltext

10/10/2025

🚨 Breaking News for the MPN Community

It’s rare to see a Polycythemia Vera (PV) therapy mentioned on Fox Business News.

Today, Rusfertide from Protagonist Therapeutics was featured for its potential to normalize red blood cell production without worsening iron deficiency and most prominently, the potential acquisition by Johnson & Johnson.

This national spotlight is encouraging and highlights growing awareness of MPN research and treatment innovation.

----> If you like what you see on PV Reporter page, how about following us or giving us a like! The dude who runs this (David Wallace) works very hard to bring you the latest news. 👍👍

🔗 Read more:

https://seekingalpha.com/news/4503348-j-and-j-reportedly-in-talks-to-buy-protagonist

PV Reporter was created to provide “easy access” to pertinent information on Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF)

10/10/2025

🧬 New Article: Interferon Treatment for MPNs: What You Need to Know on PV Reporter.

If you're living with an MPN (PV, ET, MF) or supporting someone who is, this article covers:
• How interferon works in MPNs
• Evidence for its effectiveness across disease types
• Common side effects and how patients manage them
• Considerations for younger patients and during pregnancy
• Key questions to discuss with your hematologist

🔗 Learn more:

Explore how interferon therapy helps treat MPNs like PV, ET, and early MF. Learn about its benefits, side effects, and why it’s ideal for younger patients.

10/07/2025

Akriti G. Jain, MD, discusses the role of ruxolitinib for the treatment with polycythemia vera and myelofibrosis.

Akriti G. Jain, MD, discusses the role of ruxolitinib for the treatment with polycythemia vera and myelofibrosis.

10/02/2025

🔬 New research reveals how toxic exposures may drive blood cancers

Research from Montefiore Einstein shows 9/11 first responders exposed to toxic dust had much higher rates of clonal hematopoiesis (CH), a blood cancer precursor.

Key points:
• Exposed responders with CH had nearly 6× higher risk of leukemia
• The culprit appears to be the IL1RAP protein, driving inflammation
• Targeting IL1RAP may help stop mutated blood cells from expanding

This finding may also apply to wildfire smoke, burn pits, and air pollution.
🔗

A study led by researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) has found that mutations in blood-forming cells may explain the increased risk for leukemia and other blood disorders among first responders exposed to the 9/11 World Trade....